Indivior Pharmaceuticals, Inc. (INDV) Financial Statements
$34.47NASDAQ: INDVMarket Cap $4.30B
Indivior Pharmaceuticals, Inc. most recently reported annual revenue of $1.2B, net profit of $210.0M. Revenue grew at an average annual rate of 13.9% over the last 5 fiscal years. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.
Indivior Pharmaceuticals, Inc.: Revenue rose from $969.0M in 2016 to $1.2B in 2025, a change of +27.9% over 9 years; net profit was positive in 7 of 10 reported years; operating margin moved from 34.9% to 21.4%, a shift of -13.5 percentage points; the most recent year shows net profit of $210.0M.
Income Statement — 10 Years (USD millions)
Metric
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Revenue
$969.0M
$1.1B
$960.0M
$785.0M
$647.0M
$791.0M
$901.0M
$1.1B
$1.2B
$1.2B
Operating Expenses
$631.0M
$725.0M
$643.0M
$607.0M
$803.0M
$578.0M
$982.0M
$1.2B
$1.2B
$974.0M
Operating Profit
$338.0M
$423.0M
$317.0M
$178.0M
$-156.0M
$213.0M
$-81.0M
$-156.0M
$32.0M
$265.0M
Operating Margin
34.9%
36.9%
33.0%
22.7%
-24.1%
26.9%
-9.0%
-14.3%
2.7%
21.4%
Other Income
$-51.0M
$-56.0M
$-14.0M
$2.0M
$-17.0M
$-23.0M
$-8.0M
$7.0M
$-18.0M
$-26.0M
Interest
$51.0M
$49.0M
$31.0M
$22.0M
$24.0M
$26.0M
$29.0M
$35.0M
$41.0M
$45.0M
Depreciation
$14.0M
$13.0M
$16.0M
$28.0M
$26.0M
$22.0M
$16.0M
$15.0M
$28.0M
$20.0M
Profit Before Tax
$90.0M
$144.0M
$266.0M
$180.0M
$-173.0M
$190.0M
$-89.0M
$-149.0M
$14.0M
$239.0M
Tax
$64.3M
$57.7M
$1.1M
$25.6M
$14.4M
$-7.9M
$49.4M
$13.4M
$78.6M
$12.1M
Net Profit
$32.0M
$61.0M
$263.0M
$134.0M
$-148.0M
$205.0M
$-44.0M
$-129.0M
$2.0M
$210.0M
EPS
$0.22
$0.41
$1.75
$0.92
$-1.08
$1.31
$-0.37
$-0.91
$0.02
$1.64
Dividend Payout
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Quarterly Results — Last 12 Quarters (USD millions)
7 duplicate period labels in the source data were collapsed.
Metric
Sep '23
Dec '23
Mar '24
Jun '24
Sep '24
Dec '24
Mar '25
Jun '25
Sep '25
Dec '25
Mar '26
Jun '26
Revenue
$271.0M
$293.0M
$284.0M
$299.0M
$307.0M
$299.0M
$266.0M
$302.0M
$314.0M
$358.0M
$317.0M
$343.0M
Operating Expenses
$454.0M
$232.0M
$209.0M
$417.0M
$303.0M
$203.0M
$200.0M
$230.0M
$215.0M
$236.0M
$180.0M
$183.0M
Operating Profit
$-183.0M
$61.0M
$75.0M
$-118.0M
$4.0M
$96.0M
$66.0M
$72.0M
$99.0M
$122.0M
$137.0M
$160.0M
Operating Margin
-67.5%
20.8%
26.4%
-39.5%
1.3%
32.1%
24.8%
23.8%
31.5%
34.1%
43.2%
46.6%
Interest
$10.0M
$9.0M
$8.0M
$9.0M
$10.0M
$13.0M
$12.0M
$15.0M
$12.0M
$6.0M
$7.0M
$2.0M
Profit Before Tax
$-181.0M
$62.0M
$73.0M
$-121.0M
$-1.0M
$88.0M
$59.0M
$62.0M
$37.0M
$81.0M
$115.0M
$160.0M
Tax
$25.4M
$12.9M
$15.1M
$19.0M
$500.0M
$31.8M
$18.6M
$71.0M
$-13.5M
$-25.9M
$22.6M
$23.8M
Net Profit
$-135.0M
$54.0M
$61.0M
$-97.0M
$4.0M
$59.0M
$47.0M
$18.0M
$42.0M
$102.0M
$89.0M
$122.0M
EPS
$-0.94
$0.38
$0.45
$-0.72
$0.03
$0.45
$0.38
$0.14
$0.33
$0.82
$0.69
$0.95
Over the 10 years reported for Indivior Pharmaceuticals, Inc., borrowings decreased from $535.0M in 2016 to $351.0M in 2025, cash stood at $195.0M in the latest year, shareholders' equity was $62.0M, current assets covered current liabilities 0.71 times.
Balance Sheet — 10 Years (USD millions)
Metric
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total Assets
$1.2B
$1.4B
$1.5B
$1.7B
$1.5B
$1.8B
$1.8B
$1.8B
$1.3B
$1.2B
Current Assets
$990.0M
$1.2B
$1.3B
$1.4B
$1.2B
$1.4B
$1.3B
$1.3B
$839.0M
$652.0M
Cash
$692.0M
$863.0M
$924.0M
$1.1B
$858.0M
$1.1B
$778.0M
$316.0M
$319.0M
$195.0M
Inventory
$41.0M
$52.0M
$78.0M
$73.0M
$93.0M
$95.0M
$115.0M
$135.0M
$178.0M
$153.0M
Receivables
$205.0M
$257.0M
$278.0M
$204.0M
$219.0M
$202.0M
$220.0M
$254.0M
$254.0M
$255.0M
Fixed Assets
$27.0M
$54.0M
$57.0M
$107.0M
$103.0M
$95.0M
$85.0M
$124.0M
$139.0M
$170.0M
Capital Work in Progress
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
Investments
$0
$15.0M
$33.0M
$0
$0
$0
$218.0M
$135.0M
$27.0M
$28.0M
Other Assets
$0
$0
$0
$0
$0
$0
$0
$0
$2.0M
$0
Total Liabilities
$1.5B
$1.6B
$1.5B
$1.4B
$1.4B
$1.6B
$1.7B
$2.0B
$1.7B
$1.3B
Current Liabilities
$1.0B
$854.0M
$818.0M
$742.0M
$599.0M
$804.0M
$1.0B
$1.3B
$939.0M
$914.0M
Borrowings
$535.0M
$482.0M
$241.0M
$293.0M
$285.0M
$286.0M
$277.0M
$283.0M
$375.0M
$351.0M
Other Liabilities
$969.0M
$1.2B
$1.2B
$1.1B
$1.2B
$1.3B
$1.4B
$1.7B
$1.3B
$951.0M
Equity
$72.0M
$72.0M
$73.0M
$73.0M
$73.0M
$70.0M
$68.0M
$68.0M
$62.0M
$62.0M
Reserves
$-295.0M
$-203.0M
$66.0M
$209.0M
$82.0M
$203.0M
$51.0M
$-191.0M
$-348.0M
$-98.0M
For Indivior Pharmaceuticals, Inc., operating cash flow was positive in 6 of 10 reported years; free cash flow in the latest year was negative at $94.0M; free cash flow was positive in 6 of 10 years; financing activities used $10.0M in the latest year, which covers debt repayment, dividends and buybacks.
Cash Flow Statement — 10 Years (USD millions)
Metric
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Operating Cash Flow
$407.0M
$295.0M
$303.0M
$151.0M
$-193.0M
$353.0M
$-4.0M
$-300.0M
$36.0M
$-27.0M
Investing Cash Flow
$-70.0M
$-86.0M
$-45.0M
$-9.0M
$-8.0M
$-48.0M
$-227.0M
$-148.0M
$38.0M
$-133.0M
Financing Cash Flow
$0
$0
$0
$-9.0M
$-7.0M
$-109.0M
$-90.0M
$-33.0M
$-175.0M
$-10.0M
Net Cash Flow
$225.0M
$171.0M
$61.0M
$136.0M
$-202.0M
$244.0M
$-328.0M
$-458.0M
$3.0M
$-124.0M
Free Cash Flow
$372.0M
$252.0M
$262.0M
$144.0M
$-197.0M
$319.0M
$-9.0M
$-353.0M
$5.0M
$-94.0M
Valuation & Return Ratios
Metric
Value
PEG Ratio
0.07
EV / EBITDA
10.59
FCF Yield
-2.56%
Quick Ratio
0.66
Interest Coverage
19.19
Return 1Y
46.02%
Return 3Y
53.27%
Return 5Y
166.99%
Indivior Pharmaceuticals, Inc. (INDV) financials — frequently asked questions
What is Indivior Pharmaceuticals, Inc.'s annual revenue?
Indivior Pharmaceuticals, Inc. (INDV) reported annual revenue of $1.2B in its most recent fiscal year.
What is Indivior Pharmaceuticals, Inc.'s net profit?
Indivior Pharmaceuticals, Inc. (INDV) reported net profit of $210.0M in its most recent fiscal year.
What is INDV EV/EBITDA?
Indivior Pharmaceuticals, Inc.'s enterprise value to EBITDA (EV/EBITDA) ratio is 10.59.